![]() |
市場調查報告書
商品編碼
1451893
2024-2032 年按類別、應用(社區獲得性呼吸道感染、泌尿道感染、牙科等)、藥物來源、活性譜、藥物類型和地區分類的口服抗生素市場報告Oral Antibiotics Market Report by Class, Application (Community-acquired Respiratory Tract Infections, Urinary Tract Infections, Dental and Others), Drug Origin, Spectrum of Activity, Drug Type, and Region 2024-2032 |
2023年,全球口服抗生素市場規模達到204.014億美元。展望未來, IMARC Group預計到2032年,市場規模將達到276.122億美元,2024-2032年複合年成長率(CAGR)為3.32%。傳染病的日益流行、老年人口的擴大、針對抗藥性細菌的有效治療的需求不斷增加,以及個人化醫療和基因組學的成長趨勢是推動市場的一些關鍵因素。
口服抗生素是主要用於抑制細菌生長或消除體內細菌的藥劑。它們通常透過口腔服用,並在廣泛的醫療應用中使用。口服抗生素治療的感染類型各不相同,包括皮膚、耳朵、喉嚨和泌尿道感染等常見疾病,以及某些類型的肺炎等更複雜的疾病。這些抗生素分為不同的類別,每種抗生素都有不同的作用機轉。一些常用的處方類別包括青黴素類、氟喹諾酮類、四環素類和大環內酯類。每一類針對不同類型的細菌,對特定細菌感染更有效。例如,青黴素廣泛用於治療鏈球菌感染,而氟喹諾酮類藥物則可用於對抗某些革蘭氏陰性細菌。因此,口服抗生素是現代醫療保健的關鍵要素,並被醫療保健專業人員廣泛使用,以成功治療多種細菌感染。
傳染病的日益普及以及公眾對這些疾病的可用治療方案的認知不斷提高,是支持市場成長的主要因素。此外,越來越多的老年人口更容易發生此類感染,這是推動市場成長的另一個主要因素。此外,抗生素管理計畫增加,旨在鼓勵抗生素的廣泛使用,減緩抗生素抗藥性的出現,並確保這些藥物的長期有效性。同時,日益嚴重的抗生素抗藥性問題迫使研究人員和製藥公司修改現有類別並開發能夠治療多重抗藥性細菌的新抗生素,從而加快產品採用率。此外,領先的製藥公司和研究機構正在藥物發現過程中利用人工智慧(AI)和機器學習(ML)來預測細菌抗藥性模式,了解藥物與細菌的相互作用,並加快新型抗生素的發現。與此一致的是,個人化醫療和基因組學的出現促進了市場的成長,其中個人化醫療和基因組學涉及透過考慮患者的基因組成等因素來為個別患者量身定做抗生素治療,以提高治療效果並最大限度地減少副作用。其他因素,包括對抗藥性細菌有效治療的需求不斷增加、醫療基礎設施的改善、新型口服抗生素的不斷推出以及對研發(R&D)活動的大量投資,預計也將推動未來市場的成長年。
The global oral antibiotics market size reached US$ 20,401.4 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 27,612.2 Million by 2032, exhibiting a growth rate (CAGR) of 3.32% during 2024-2032. The increasing prevalence of infectious diseases, expanding geriatric population, escalating demand for effective treatments against drug-resistant bacteria, and the growing trend of personalized medicine and genomics represent some of the key factors driving the market.
Oral antibiotics are pharmaceutical agents primarily prescribed to inhibit bacterial growth or eliminate bacteria from the body. They are usually taken by mouth and are utilized across a wide range of medical applications. The types of infections treated by oral antibiotics vary and include common ailments such as skin, ear, throat, and urinary tract infections and more complex conditions like certain types of pneumonia. These antibiotics are categorized into different classes, each with a distinct mechanism of action. Some commonly prescribed classes include penicillins, fluoroquinolones, tetracyclines, and macrolides. Each class targets different types of bacteria and is more effective for specific bacterial infections. For instance, penicillins are widely used for streptococcal infections, while fluoroquinolones may be chosen to combat certain gram-negative bacteria. As a result, oral antibiotics are a key element of modern healthcare and are widely prescribed by healthcare professionals to enable the successful treatment of numerous bacterial infections.
The increasing prevalence of infectious diseases and the rising public awareness about the available treatment options for these conditions represent the primary factors supporting market growth. Moreover, the expanding geriatric population that is more susceptible to developing such infections is another major factor fueling the market growth. In addition, there has been a rise in antibiotic stewardship programs aimed at encouraging the widespread use of antibiotics, slowing down the emergence of antibiotic resistance, and ensuring the prolonged effectiveness of these drugs. Along with this, the growing issue of antibiotic resistance has compelled researchers and pharmaceutical companies to modify existing classes and develop new antibiotics capable of treating multi-drug resistant bacteria, thereby accelerating the product adoption rate. Furthermore, the leading pharmaceutical companies and research institutes are leveraging artificial intelligence (AI) and machine learning (ML) in the drug discovery process to predict bacterial resistance patterns, understand drug-bacteria interactions, and expedite the discovery of novel antibiotics. In line with this, the emergence of personalized medicine and genomics, which involves tailoring antibiotic treatment to individual patients by considering factors such as their genetic makeup to enhance treatment effectiveness and minimize side effects, has catalyzed market growth. Other factors, including escalating demand for effective treatments against drug-resistant bacteria, improving healthcare infrastructure, the continual launch of novel oral antibiotics, and heavy investments in research and development (R&D) activities, are also anticipated to propel the market growth in the coming years.
IMARC Group provides an analysis of the key trends in each segment of the global oral antibiotics market, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on the class, application, drug origin, spectrum of activity, and drug type.
Beta Lactam and Beta Lactamase Inhibitors
Penicillin
Cephalosporin
Others
Quinolone
Macrolide
Others
The report has provided a detailed breakup and analysis of the oral antibiotics market based on the class. This includes beta lactam and beta lactamase inhibitors (penicillin, cephalosporin, and others), quinolone, macrolide, and others. According to the report, beta lactam and beta lactamase inhibitors represented the largest segment.
Community-acquired Respiratory Tract Infections (CARTIs)
Upper Respiratory Tract Infections (URTI)
Lower Respiratory Tract Infections (LRTIs)
Urinary Tract Infections (UTIs)
Dental
Combination
Monotherapies
Others
A detailed breakup and analysis of the oral antibiotics market based on the application has also been provided in the report. This includes community-acquired respiratory tract infections (upper respiratory tract infections (URTI) and lower respiratory tract infections (LRTIs)), urinary tract infections (UTIs), dental (combination and monotherapies), and others. According to the report, urinary tract infections (UTIs) accounted for the largest market share.
Natural
Semisynthetic
Synthetic
The report has provided a detailed breakup and analysis of the oral antibiotics market based on the drug origin. This includes natural, semisynthetic, and synthetic. According to the report, synthetic represented the largest segment.
Broad-spectrum Antibiotic
Narrow Spectrum Antibiotic
A detailed breakup and analysis of the oral antibiotics market based on the spectrum of activity has also been provided in the report. This includes broad-spectrum antibiotic and narrow spectrum antibiotic.
Branded
Generics
The report has provided a detailed breakup and analysis of the oral antibiotics market based on the drug type. This includes branded and generics.
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia-Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, Asia-Pacific was the largest market for oral antibiotics. Some of the factors driving the Asia-Pacific oral antibiotics market included its aging population, growing burden of infectious diseases, high healthcare expenditure, the presence of various key players, etc.
The report has also provided a comprehensive analysis of the competitive landscape in the global oral antibiotics market. Detailed profiles of all major companies have been provided. Some of the companies covered include Bayer AG, Cipla Inc., Gilead Sciences Inc., Janssen Inc. (Johnson & Johnson Services, Inc.), Pfizer Inc., Roche Holding AG, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.